Harpoon: Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition
The deal includes a T-cell engager in clinical development for lung cancer and neuroendocrine tumours
Read full article »
CEO
- -Harpoon is a California-based biotechnology company that researches and develops T-cell immunotherapies for the treatment of cancer and infectious diseases.
Read more